Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer(KATANA E3M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer(KATANA E6M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 |
| Apr 27, 2025 |
| clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04225299 | Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | withdrawn | Phase 3 | 0 | Steba Biotech S.A.OTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03488810 | Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer(ARN-509) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 17, 2020 | clinicaltrials |
| NCT02053311 | Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | withdrawn | Phase 3 | 0 | Swiss Cancer InstituteOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT00691899 | A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT00922129 | Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00043212 | Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective. | withdrawn | Phase 3 | 0 | Northwest BiotherapeuticsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00258466 | Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer | withdrawn | Phase 3 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00728533 | Open-Label, Randomised Parallel-Group Study | withdrawn | Phase 3 | 0 | Ferring PharmaceuticalsINDUSTRY | 0 | Mar 18, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Apr 27, 2025source: clinicaltrials